Research programme: inflammatory disease therapeutics - Janssen/Second Genome

Drug Profile

Research programme: inflammatory disease therapeutics - Janssen/Second Genome

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Biotech; Second Genome
  • Developer Janssen Biotech; Mayo Clinic; Second Genome
  • Class Peptides; Small molecules
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Inflammatory bowel diseases
  • No development reported Ulcerative colitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Ulcerative-colitis in USA
  • 07 Oct 2014 Second Genome enters into a collaboration with Mayo Clinic Center to support development of therapeutics for multiple disease indications, including inflammatory bowel disease
  • 07 Oct 2014 Early research in Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top